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Background: We conducted a survey of the infection burden associated with the implantation of cardiac
implantable electronic devices (CIEDs) in Japan.
Methods: The institutes were selected using annual device implantation data provided by Medtronic
Japan Co., Ltd. The data sampling period was from January 1 to December 31, 2013. Institutes were
classiﬁed into Group P, at which only pacemakers were implanted, and Group A, at which other CIEDs
were implanted. Group P was further classiﬁed into three sub-groups by implantation number. The
infection rate was compared between groups using logistic regression analysis.
Results: A total of 129 of 138 institutes responded. The annual infection rate was 1.12% for overall CIEDs.
The institute at which 15–29 pacemakers were implanted had a high infection rate (2.11%). No statisti-
cally signiﬁcant difference was observed (adjusted p¼0.1131). The overall migration rate was 0.50%.
Complete removal of the CIED system was performed in 55.8% of patients who underwent implantation.
Conclusions: This survey was the ﬁrst on CIED infection and migration in Japan. The CIED infection rate
(1.12%) was similar to that previously reported. A high infection rate (2.77%) was observed in the
infection experienced institutes.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular implantable electronic device (CIED) treatment
is indispensable as cardiac treatment, and the implantation
number of CIEDs has signiﬁcantly increased over the past several
years [1–3]. Increase in implantable cardioverter deﬁbrillator (ICD)
implantation is responsible for the increasing number of CIED
implantations [4]. With this trend, augmenting CIED infection has
become concerning. CIED infection has detrimental effects on
mortality and increases ﬁnancial burden [3–5]. Therefore, guide-
lines for the management of CIED infection were recently updated
[5,6]. When a patient is diagnosed with CIED infection, even if the
infection is restricted locally to the pocket, complete removal of
the CIED system is required by guidelines [5,6]. However, a
nationwide study on CIED infection has not been conducted in
Japan. This survey is the ﬁrst to investigate the current status of
CIED infection and migration in Japan.blished by Elsevier B.V. This is an
akajima),2. Methods
From October 27, 2014 to December 12, 2014, a survey on device
infection and migration was conducted in Japan. The number of
cases of device infection or migration after CIED implantation was
assessed retrospectively. Respondents did not necessarily undergo
CIED implantation. The institutes at which pacemakers, ICDs, car-
diac resynchronization therapy pacemakers (CRT-Ps), or cardiac
resynchronization therapy deﬁbrillators (CRT-Ds) were implanted
from January 1 to December 31, 2013 were selected using annual
device implantation data provided by Medtronic Japan Co., Ltd.
Patients who reported infection(s) during that period, and the
infection or migration incidents that occurred from January 1, 2013
and December 12, 2014 were included in this study. The implant
was not categorized based on whether it was a new or replacement
device. All applicable events were counted regardless of manu-
facturer. The sample size was calculated based on the following
assumptions. An 80% power at a signiﬁcance level of 0.05 was the
goal. The estimated annual infection rates are 0.6% for pacemakers
[9], and for all other CIEDs, the estimated annual infection rate is
2.8%, which is derived from the infection rate of each device type
and annual implant number. Estimation accuracy of the 95% con-
ﬁdence interval was set at 70.6% for the pacemaker group and
72.8% for all other CIEDs group. After applying an attrition rate ofopen access article under the CC BY-NC-ND license
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above criteria. With regard to data collection, referred cases were
excluded. Speciﬁc information collected was treatment for infection
and complications due to migration. The questionnaire is shown in
Table 1, and the original language was Japanese.
Statistical analyses were performed with SAS Ver. 9.3. A p-value
less than 0.05 was used to assess statistical signiﬁcance.3. Results
3.1. Institutes
A total of 138 institutes from each geographical area in Japanwere
randomly chosen. One hundred twenty-nine institutes responded to
the survey. The response rate was 93.5%. A total of 84.5% (109 sites) of
institutes at which only pacemakers were implanted and 15.5% (20
sites) at which other CIEDs were implanted responded to the survey.
The total number of implantation cases was 3840: 3331 pacemaker
cases (86.7%) and 509 other CIED cases (13.3%).
3.2. Infection burden
The duration that the survey covered was 1 year from January
1, 2013 to December 31, 2013. New device implantation and
replacement were not distinguished in the analysis. We identiﬁed
43 cases of device infection. The overall infection rate was 1.12%
(95% CI: 0.812–1.505); however, the rate was 2.77% at the sites
with more experience with implantation.
The infection rates according to the device type were 1.08% in
pacemakers and 1.38% in other CIEDs (Table 2). The infection rates
according to institute type were 1.18% in the institutes at which
only pacemakers were implanted and 1.05% in the institutes at
which other CIEDs were implanted (Table 3.)
Infection occurred within 1 year of implantation in 35 cases
(81.4%) and more than 1 year in 8 cases (18.6%). Regarding treat-
ments for infection, complete CIED system removal was performed
in 24 cases (55.8%), generator removal in 11 cases (25.6%),
administration or prolongation of antibacterial drugs or both in
7 cases (16.3%), and movement of the pocket to the opposite side
in 1 case (2.33%) (Fig. 1).Table 1
Survey questionnaire.
Question
The number of the CIED implantations in 2013
The number of CIED infection and migration.
The time infection occurred, within 1 year or more than 1 year
Treatment for infection
Complication due to migration
Treatment for migration
CIEDs: ICD, CRT-D, CRT-P.
Table 2
Comparison of the infection rate between pacemakers and other CIEDs.
Devices Operation numbers Infection numbers Infec
Pacemakers 3331 36 1.08
Other CIEDsb 509 7 1.375
Total 3840 43 1.120
CI, Conﬁdence interval; RR, relative risk.
a Fisher exact test.
b other CIEDs: ICD, CRT-D, CRT-P.3.3. Device migration
Nineteen device migration cases were identiﬁed. The overall
migration rate was 0.50% (95% CI: 0.298–0.772). There were 19 com-
plications due to device migration. These complications included lead
dislodgment in 14 cases (73.7%), and perforation, lead fracture, and
infection in 1 case each (15.8%), and an unknown complication in
2 cases (10.5%). Migrationwas treated by lead repositioning in 10 cases
(52.6%), whole CIED system extraction and re-implantation in 2 cases
(10.5%), and observation alone in 3 cases (15.8%). Lead extraction with
an additional procedure was performed in 2 cases (10.5%).4. Discussion
4.1. Quality and quantity of the survey
To review implant status as a whole, private annual device
implantation data provided by Medtronic Japan Co., Ltd., were
used in this survey. The private data may introduce bias; however,
the data showed good correlation in the annual implantation
number with the data from the Japan Arrhythmia Device Industry
Association. The geographical area coverage rate of this survey was
93.6% (44 out of 47 prefectures). The variance of the annual
implantation numbers among the institutes was 1–221. Out of
randomly selected sites sampled from the above data, 93.5% of the
institutes replied to the questionnaire. Therefore, the ﬁndings of
this survey are well representative of the entire Japanese CIED
infection rate, and this study is the ﬁrst of its kind in Japan.
The data did not include personal data such as patients’
demographics, physicians’ experience, and details on the time of
infection occurrence.
4.2. Infection burden
The overall infection rate was 1.12% and it was similar or lower than
that previously reported in the USA and Europe [1,4,8,10,11]. In the
European survey [7], the number of infection-free institutes was 27.1%
(13/48). In this survey, 76.7% of the enrolled institutes did not experi-
ence device infection, and this rate is higher than that observed by the
European survey. Nevertheless, the data from this survey cannot be
compared with that from previous studies in the USA and Europe,
because the background of the enrolled institutes may be different. One
difference was that this survey included institutes with a low implant
volume. The limitation of the European survey [7] was the low number
of small volume institutes. The same survey showed that at 62.5% of
the enrolled institutes, more than 200 devices were implanted per year.
In contrast with this ﬁnding, less than 50 devices were implanted at
82.2% of the institutes in this survey and at 9.30% of the institutes, only
1 device per year was implanted. These ﬁndings reﬂect the number of
small volume institutes in Japan. In a small volume institute, only
1 case of infection may reﬂect a high infection rate, e.g., the infection
rate would be 100% at an institute at which only 1 implantation per
year is performed if the patient contracts infection.tion rate (%) Exact-95% CI (min-MAX ) RR p-Valuea




Comparison of the infection rate between institutes: pacemakers only and other CIEDs.
Institute Institution numbers Operation numbers Average implantation Infection numbers Infection rate (%) Exact-95% CI (min-MAX) RR p-Valuea
Pb 109 2037 18.7 24 1.178 0.756–1.748 0.89 0.7603
Ac 20 1803 90.2 19 1.054 0.636–1.641
Total 129 3840 29.8 43 1.120 0.812–1.505
CI, Conﬁdence interval; RR, relative risk.
a Fisher exact test.
b P: The institutes at which only pacemakers were implanted.
c A: The institutes at which all other CIEDs were implanted.
Fig. 1. Comparison of the Group P subgroups with Group A. Group P was classiﬁed into three sub-groups based on the number of implantations. Group P1 included the institutes in
which less than 14 devices per year were implanted. Institutes at which 15–29 implantations were performed were classiﬁed as Group P2. The institutes at which more than 30
implantations were performed were classiﬁed as Group P3. The infection rate of Group P2was 2.11%, and it was higher than that of the other groups and the infection rate in the US
in 1996 [4]; dotted line. The infection rate in Group P2 was compared with that of the other groups using logistic regression analysis. The results of the analysis showed the
inferiority of Group P2 to Group P3 with respect to the infection rate. However, no statistically signiﬁcant difference was observed after Bonferroni correction.
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than that reported by previous studies in the USA and Europe.
Greenspon et al. studied the trend of device infection from 1993 to
2008 in the USA using the Nationwide Inpatient Sample (NIS) dis-
charge records [4]. The infection rate was 1.53% in 2004 and 2.41% in
2008. The infection rate in this survey (1.12%) was lower than that in
Greenspon et al.’s study. While ICD implantation represented 35% of
all CIED implantations in Greenspon et al.’s study, the implantation
rate of ICDs and CRTs was only 13.3% in this survey. Therefore the
two values cannot be compared. For this reason, we intended to
normalize the results to the data in the literature [4] with the same
ICD implantation rate. In the literature, the trend graph of the annual
number of CIED implantations from 1993 to 2008 is shown in Fig. 1
of the article. According to the ﬁgure, the ICD implantation rate in
1996 was the same as that in this survey (approximately 13%). The
infection rate was able to read from it and the rate was approxi-
mately 1.3%. This value is similar to the infection rate in this survey.
To reduce the rate of CIED infection, the importance of pre-
operative antibiotic prophylaxis has been discussed [8,12,13]. de
Oliveira et al. [14] studied the efﬁcacy of perioperative antibiotic
prophylaxis in a prospective, randomized, double-blinded,
placebo-controlled trial. The study was terminated by the safety
committee due to a signiﬁcant difference in favor of the antibiotic
arm. The infection rate of the control arm, which administrated
placebo, was 3.28%, whereas that in the prophylactic antibiotic
administration arm was 0.63%. Almost 100% of institutes in Japanadminister antibiotics pre- and perhaps postoperatively. This
prophylaxis is thought to contribute to the reduction in the
infection rate in Japan. Assuming that all the institutes in this
survey administered prophylactic antibiotics, the annual infection
rate, which is1.12% in this survey, is much higher than that in the
prophylaxis group in de Oliveira et al.’s study (0.63%.)
In Japan, ICDs and CRTs are implanted only in institutes certi-
ﬁed by the Japanese Heart Rhythm Society. On the other hand, no
such regulations apply for implantation of pacemakers. Accord-
ingly, the institutes were classiﬁed as all CIED-approved institutes
(Group A) and pacemaker institutes (Group P), and the infection
rate was compared between these groups (Table 3). There was no
statistical signiﬁcance between the two groups in the annual
infection rate (p¼0.7603.)
Some studies found that infection rate of ICDs was higher than
that of peacemakers [9,11], and CRT is a risk factor for CIED
infection [14]. In this survey, the annual infection rate of ICDs and
CRT was 1.05% and that of pacemakers was 1.18% in the certiﬁed
institutes, with no statistically signiﬁcant difference in the infec-
tion rate between pacemakers and ICDs.
Al-Khatib et al. [15] analyzed the relationship between physician
experience and ICD infection rate, and found an association
between a higher volume of ICD implantations and a lower rate of
infections. Unfortunately, the infection rate in the groups was not
reported. However, the total number of implantations and the
infection numbers are shown in a table in the literature. The
Fig. 2. Treatment of infection: Comparison of Group P with A. 50% of infections in Group P and 63% in Group Awere treated with complete removal of the CIED system. There
was no statistically signiﬁcant difference between groups in the total removal rate. Overall complete removal rate was 56%.
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29 implantations was 0.9%. On the other hand, 3 of 6 institutes in
which more than 18 CEIDs were implanted without pacemakers
experienced infections with an infection rate of 0.70% in Japan.
Implantation numbers were 15–29 in Group P, and the propor-
tion of institutes with more experience with infections was 42.9%.
The number is similar to that of other CIEDs in Group A. However,
the average implantation number in Group P was signiﬁcantly
smaller than that in Group A. The infection rate in Group P was
1.18%, which is almost equal to the infection rate in the US, in which
35% of implantations were those for ICDs in 2008 [4]. Group P was
classiﬁed into 3 sub-groups based on the number of implantations.
Group P1 included institutes at which less than 14 devices per year
were implanted, and Group P2 included institutes at which 15–29
devices per year were implanted, and Group P3 included institutes
at which 30 CIEDs were implanted. According to Al-Khatib’s study
[15], less experienced physicians had less in patient mortality and
more mechanical complications, and this group showed better
infection rate than the relatively experienced physicians group. The
same trend was observed in this survey. The infection rate in Group
P1, which included the fewest CIED implantations, was not inferior
to that of Group P2. The CIED infection rate does not seem to be
related to either skill or implantation number.
The infection rate in the three P sub-groups and Group A was
compared using logistic regression analysis (Fig. 2). The results of
the analysis showed the inferiority of Group P2 to P3 (p¼0.0377).
However, no statistical signiﬁcance was observed after p value
adjustment using Bonferroni correction (p¼0.1131.) This analysis
was validated comprehensively using the Cochran–Mantel–
Haenszel general association test. Statistical signiﬁcance was not
observed in all groups (p¼0.0934).
In this survey, 76.7% of the participating institutes did not experi-
ence the infection, which was a high rate. However in the remaining
institutes (23.3%) that experienced infection, most had high infection
rates (2.77%) despite prophylactic antibiotic use as the standard of
care. To reduce the rate of CIED infection in Japan, the root cause of the
infection should be identiﬁed. However, in this survey few parameters
were assessed and hence risk stratiﬁcation was not performed. In this
survey, the operations were not categorized as new device implanta-
tion, device replacement, up-grade operation, or reoperation due to
system failure. However, many studies have emphasized that device
replacement is a risk factor for infection [7,15–17].
4.3. Device migration
Device migration is a serious complication of CIED implantation.
The causes of device migration are thought to be the device size and
procedure. Device migration sometimes causes lead complications
and most require reoperation. Reoperation is regarded as a risk factorfor CIED infection [8,16–18]. No survey or study has focused on
device migration; therefore this survey is unique.
It is notable that the overall migration rate was 0.50%, and the
rate of ICD and CRT (0.20%) infection is lower than that of pace-
makers (0.54%). Migrations induced a high rate of lead dislodge-
ment (73.7%) that require reoperation, which is an additional risk
factor for infection. Therefore, this survey showed that device
migration was an important factor for device infection.
Studies focusing on the clinical mechanism of migration and
identiﬁcation of the appropriate surgical procedure to prevent
device migration are important.
4.4. Treatment of CIED infection
Even if CIED infection is only observed locally in the pocket,
complete removal of the CIED system, i.e., device and lead(s), should
be performed [5–7]. Annual system removal rate in this survey was
55.8%. The removal rate was 50.0% in Group P and 63.2% in Group A.
There was no statistical signiﬁcance between the two groups (Fig. 2).
This rate is higher than that in the European survey, which was 43.5%.
Device removal is a conventional method to treat CIED infection and is
recommended in the guidelines. The recurrence rate of CIED infection
is higher if device removal and debridement are performed for device
infection [18]. In this survey, device removal was performed in 11
cases, but details of the treatment were not available.
4.5. Study limitations
Even though the data were obtained from a geographically wide
area and are from various institutions, a retrospective questionnaire
survey was used for collection. Hence, individual patient data,
physician experience, and treatment detail were not collected.5. Conclusions
This survey was the ﬁrst on CIED infection and migration in
Japan. The rate of CIED infection was 1.12%, which was similar to
that previously reported in the USA and Europe. The burden
resulted from the high rate of infection-free institutes. However
the high infection rate (2.77%) was observed in institutes with
more experience with infection. Device migration occurred more
frequently than expected, and 73.7% of migrations were caused by
lead insufﬁciency. In more than 50% of cases, the CIED system was
completely removed.
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